Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT01515735 Recruiting - Clinical trials for Pseudoexfoliation Syndrome

LOXL1 Polymorphism in Pseudoexfoliation Syndrome

Start date: December 2011
Phase: N/A
Study type: Observational

To evaluate the association profiles of the lysyl oxidase-like 1 gene polymorphisms with pseudoexfoliation syndrome in the Korean population, Genotypes of lysyl oxidase-like 1 gene were analyzed by direct sequencing.

NCT ID: NCT01515631 Completed - Alagille Syndrome Clinical Trials

Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review

Start date: April 2007
Phase:
Study type: Observational

Patients who have Alagille Syndrome (AGS) also frequently have blockages (or "stenoses") of their pulmonary arteries. Little is known about the degree or variability of these stenoses, or the effect of this disease on the right ventricle (the chamber of the heart which pumps blood to the lungs). This study will first quantify and describe pulmonary artery stenosis in patients with Alagille Syndrome. The study will also assess the effect of these stenoses on the right ventricle. The investigators hope to learn the degree and characteristics of pulmonary artery stenosis in Alagille Syndrome. The investigators also hope to learn the effect of this pulmonary artery stenosis on the right ventricle in patients with Alagille Syndrome. This information is critical in the management of patients with Alagille syndrome, as there is currently no data to guide clinicians on the management of pulmonary artery stenosis. Furthermore, the information from this study may help physicians manage pulmonary artery stenosis in other patients as well.

NCT ID: NCT01515462 Completed - Clinical trials for Wiskott-Aldrich Syndrome (WAS)

Gene Therapy for Wiskott-Aldrich Syndrome

TIGET-WAS
Start date: April 20, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This is phase I/II protocol to evaluate the safety and efficacy of WAS gene transfer into hematopoietic stem/progenitor cells for the treatment of Wiskott Aldrich Syndrome.

NCT ID: NCT01514461 Completed - Clinical trials for Familial Chylomicronemia Syndrome (FCS)

A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether LCQ908 is effective and safe in lowering triglycerides in subjects with Familial Chylomicronemia Syndrome (FCS) (Hyperlipoproteinemia [HLP] type I). Data from this study will be used to support a registration submission of LCQ908 20 mg and 40 mg as treatment of chylomicronemia in subjects with FCS (HLP Type 1).

NCT ID: NCT01513317 Terminated - Clinical trials for Myelodysplastic Syndrome

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Start date: November 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of siltuximab, demonstrated by a reduction in red blood cell (RBC), transfusions to treat the anemia of Myelodysplastic Syndrome (MDS).

NCT ID: NCT01512342 Completed - Clinical trials for Chronic Fatigue Syndrome

Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome

Start date: August 2011
Phase: Phase 2
Study type: Interventional

Given the lack of evidence in support of pacing self-management for patients with chronic fatigue syndrome (CFS), it is examined whether physical behavior and health status of patients with CFS improve in response to a pacing self-management program. The effects of pacing will be compared with those observed when applying relaxation therapy to patients with CFS.

NCT ID: NCT01511978 Completed - Clinical trials for Lambert-Eaton Myasthenic Syndrome

Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome

DAPPER
Start date: January 2012
Phase: Phase 2
Study type: Interventional

Hypothesis: 3,4-Diaminopyridine base (3,4-DAP) improves Lambert-Eaton Myasthenic Syndrome (LEMS)-related weakness.

NCT ID: NCT01511445 Completed - Myelopathy Clinical Trials

Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome

CASCADE
Start date: December 2011
Phase: N/A
Study type: Interventional

This study randomizes neck and arm pain patients being treated with discectomy and anterior interbody fusion into two groups: one to receive a new ceramic implant and a control group with a more traditional plastic implant. The study will measure and compare pain and disability improvement with the two products over a period of two years. The fusion status will also be judged with plane x-rays and one CT scan.

NCT ID: NCT01509768 Completed - Clinical trials for Sanfilippo Syndrome Type B

Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

Start date: April 9, 2012
Phase:
Study type: Observational

The purpose of this study is to evaluate the natural course of disease progression in Mucopolysaccharidosis Type III (MPS IIIB) patients who are untreated to identify potential surrogate endpoints that may be utilized in future treatment trials of MPS IIIB using predefined assessments including standardized clinical, biochemical, neurocognitive, developmental, and imaging measures.

NCT ID: NCT01509300 Recruiting - Solid Tumors Clinical Trials

HLA-haploidentical Hematopoietic Stem Cell Transplantation for Children and Adolescents With Acute Leukemia, Myelodysplastic Syndrome and Solid Tumors

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Conditioning with total body irradiation (TBI) and fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, T-cell depletion may contribute to prevent developing severe acute graft versus host disease (GVHD) in haploidentical transplantation. PURPOSE: This phase I/II trial is to evaluate the safety and efficacy of TBI, fludarabine, cyclophosphamide and antithymocyte globulin with T-cell depleted graft from haploidentical donors in treating patients with acute leukemia and myelodysplastic syndrome.